{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/impetigo/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"58ff6676-3c7d-5610-98c3-5e6b6b326c5c","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field 65281acd-c0f8-454e-a8f9-34d64281c6ea --><h2>Clarithromycin</h2><!-- end field 65281acd-c0f8-454e-a8f9-34d64281c6ea -->","summary":"","htmlStringContent":"<!-- begin item 9f1d4b57-c15b-4013-812f-c997c17570b4 --><!-- end item 9f1d4b57-c15b-4013-812f-c997c17570b4 -->","topic":{"id":"df142ae3-a675-5faa-955f-deba3aa176bc","topicId":"08c2a82c-2e88-477a-a00d-e75b47770e61","topicName":"Impetigo","slug":"impetigo","lastRevised":"Last revised in February 2020","chapters":[{"id":"5d5b7bff-ba78-5008-89df-49963bc208b7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"35862574-df78-5554-bbe6-86275287ef3a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"bc13ef99-c08d-5361-89de-765433a18ce3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8abd7c1c-e4d5-5fc6-9deb-2cfbbee04b6a","slug":"changes","fullItemName":"Changes"},{"id":"5105f48d-40d4-5c74-bec6-af0574471e5a","slug":"update","fullItemName":"Update"}]},{"id":"8c2bfe64-9ced-531b-b641-00b4ff18bd7c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"eaefc2a4-19e1-525e-82f4-dccc7115b2b6","slug":"goals","fullItemName":"Goals"},{"id":"5a84c42b-0cca-52ed-9924-c54417494c01","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5275b616-56f0-5b49-b2df-0cbffee7e3fc","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6ed2c217-68c2-5ecc-8c61-7187fcbead1b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1dec750c-6e33-5adf-ae33-87a7f4a042c2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"abff03ac-c7cc-5fe7-b6de-0871e4a2846a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba37e0a2-65cd-52ec-8992-3299b96c1ea0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9440ce15-e09d-57c4-9ff1-70e323defaf3","slug":"definition","fullItemName":"Definition"},{"id":"605ba802-106d-5b36-93df-7644ebd9231d","slug":"causes","fullItemName":"Causes"},{"id":"863740f1-ab66-5109-bcb1-30ef774d0d2c","slug":"incidence","fullItemName":"Incidence"},{"id":"69d86930-4301-54ce-8d47-133d348f0b7b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"afe26e4f-1499-57be-a412-9d17510303e9","slug":"complications","fullItemName":"Complications"}]},{"id":"cf492669-e436-53c8-b2b7-f369198b6622","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8dee3a55-eaa2-5aab-b6e5-9a89ad394715","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"46b7f694-9523-5232-ad5d-ca6d1dba2c94","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"6e579521-48f9-59b3-a8e3-5e8e37473653","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eebe4528-d9d4-5e2e-ab08-fe1255e1564b","fullItemName":"Management","slug":"management","subChapters":[{"id":"3f2b5528-3a31-51ee-9a7c-713b86cf2854","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"60f683cb-4447-5ecd-9b90-245b33e20336","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f5f53214-ec8d-5ca7-8dde-0ef07d26b140","slug":"hydrogen-peroxide","fullItemName":"Hydrogen peroxide"},{"id":"178eb388-927e-59ea-8289-59bd71cf7ae0","slug":"fusidic-acid","fullItemName":"Fusidic acid"},{"id":"7ee4e706-9719-555b-85eb-18477604621b","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"58ff6676-3c7d-5610-98c3-5e6b6b326c5c","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"9983753e-f306-528c-bcad-5c5e37e49831","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4825af9d-eb38-5c45-a29d-40a17e11e044","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"484c3649-34b0-537b-9431-0907ac172480","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e05d1269-8a31-569f-b89a-f9609763db8b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c7093c62-22f3-531b-ab5c-3c222fd9220e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"25fc1ec7-3a38-5636-9e71-37951cbae3e8","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f7eec7c7-f55f-53ec-afb1-6fa00707cb90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9e2f110a-ec9f-5728-8f52-cb51f2bfe209","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"60f683cb-4447-5ecd-9b90-245b33e20336","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"154d81cb-3a74-5693-afaf-e892538423c9","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 6382d8ba-44bf-428d-a305-4f405fef9b25 --><h3>What are the contraindications and cautions for clarithromycin?</h3><!-- end field 6382d8ba-44bf-428d-a305-4f405fef9b25 -->","summary":"","htmlStringContent":"<!-- begin item 24c52912-9bb6-4475-8340-79806577f199 --><!-- begin field 1d916657-6e47-4105-a689-13d17b15f50c --><p><strong>Do not prescribe clarithromycin in people:</strong></p><ul><li>With known hypersensitivity.</li><li>Taking drugs that prolong the QT interval (for example, haloperidol, sotalol, terfenadine, and pimozide) — macrolides can also prolong the QT interval, which is a risk factor for Torsades de pointes.</li><li>With a history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes.</li><li>With hypokalaemia — due to the risk of prolongation of the QT interval.</li><li>Taking HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4, (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.</li><li>Taking ergot alkaloids — concomitant administration is contraindicated, due to the risk of acute ergot toxicity.</li><li>Taking oral midazolam — can markedly increase the exposure to midazolam.</li><li>With severe hepatic impairment if they also have renal impairment.</li></ul><p><strong>Prescribe clarithromycin with caution in people with:</strong></p><ul><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT prolongation.<ul><li>There is an increased risk of death for people with coronary artery disease.</li></ul></li><li>Electrolyte disturbances, such as hypomagnesaemia.</li><li>Impaired hepatic function — clarithromycin is principally excreted by the liver.</li><li>Myasthenia gravis — macrolides may aggravate symptoms.</li><li>Severe renal impairment (eGFR less than 30 mL/min).<ul><li>Dose adjustment may be required. Avoid prolonged-release once daily tablets as the dose cannot be reduced.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">FDA, 2018</a>]</p><!-- end field 1d916657-6e47-4105-a689-13d17b15f50c --><!-- end item 24c52912-9bb6-4475-8340-79806577f199 -->","subChapters":[]},{"id":"b3a53c46-11f8-5061-a334-c111615784c7","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field f035812b-fa3c-436b-a63a-7e24c4419875 --><h3>What key adverse effects are associated with clarithromycin?</h3><!-- end field f035812b-fa3c-436b-a63a-7e24c4419875 -->","summary":"","htmlStringContent":"<!-- begin item 6e2efce9-6fe0-48a6-badc-e4f8cabe2b0e --><!-- begin field d73405db-3503-4a91-a80c-7fffd0f58203 --><ul><li><strong>Gastrointestinal </strong>— diarrhoea, vomiting, dyspepsia, nausea, abdominal pain (common), taste disturbance.<ul><li>Uncommonly: cholestatic jaundice, hepatotoxicity, anorexia.</li><li>Rarely: pancreatitis, pseudomembranous colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Nervous system</strong> — headache, dysgeusia (common), dizziness, somnolence, insomnia, tremor (uncommon), tinnitus.<ul><li>Rarely: convulsions, paraesthesia.</li></ul></li><li><strong>Psychiatric</strong> — insomnia (common), anxiety, nervousness (uncommon).<ul><li>Rarely or very rarely: psychotic disorders, depression, mania, hallucination.</li></ul></li><li><strong>Skin</strong> — rash, hyperhidrosis (common), pruritus, urticaria (uncommon).<ul><li>Rarely, or very rarely: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens Johnson syndrome, toxic epidermal necrolysis.</li></ul></li><li><strong>Other adverse effects reported rarely, or very rarely, include:</strong><ul><li>Anaphylaxis.</li><li>Arrhythmias.</li><li>Deafness.</li><li>Pancreatitis.</li><li>QT interval prolongation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">BNF 75, 2018</a>]</p><!-- end field d73405db-3503-4a91-a80c-7fffd0f58203 --><!-- end item 6e2efce9-6fe0-48a6-badc-e4f8cabe2b0e -->","subChapters":[]},{"id":"ee0ba4a5-106c-5b3a-86ad-50799d355362","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 9675c52a-ab48-4b09-988b-a75b0129de34 --><h3>What key interactions are associated with clarithromycin?</h3><!-- end field 9675c52a-ab48-4b09-988b-a75b0129de34 -->","summary":"","htmlStringContent":"<!-- begin item 21b50b59-526f-4c2b-9c54-a75b0129dd3e --><!-- begin field 123aae18-6a32-4a0c-a1c9-a75b0129de34 --><ul><li>Calcium channel blockers (CCBs) — there is an increased risk of hypotension if CCBs, such as verapamil, amlodipine, and diltiazem are taken concomitantly with clarithromycin, as they are metabolised by CYP3A4. This may also lead to increased levels of clarithromycin.</li><li>Ciclosporin — clarithromycin increases the concentration of ciclosporin. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</li><li>Colchicine — clarithromycin is predicted to increase the exposure to colchicine. Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust colchicine dose. Monitor for signs of colchicine toxicity (for example, nausea, vomiting, diarrhoea, myopathy, and pancytopenia).</li><li>CYP3A enzyme inducers (rifampicin, carbamazepine, phenobarbital) — these may induce the metabolism of clarithromycin, resulting in sub-therapeutic levels.<ul><li>It may be necessary to monitor the levels of these drugs, as CYP3A is inhibited by clarithromycin leading to higher plasma levels of the inducer.</li></ul></li><li>Digoxin — macrolides increase digoxin levels. Monitor and alter digoxin dose if required.</li><li>Edoxaban — levels may be increased by clarithromycin. Dose adjustment of edoxaban may be required.</li><li>Ergot alkaloids — concomitant administration is contraindicated, due to the risk of acute ergot toxicity.</li><li>Oral hormonal contraception — additional contraceptive precautions are not required during or after courses of clarithromycin.<ul><li>However, women should be advised that if diarrhoea, vomiting or breakthrough bleeding occur there is a possibility of contraceptive failure. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li>Oral hypoglycaemic drugs (sulfonylureas) and insulin — the concomitant use of clarithromycin and oral hypoglycaemic drugs and/or insulin can result in significant hypoglycaemia. Monitor glucose levels.</li><li>Statins (atorvastatin, simvastatin) — these are extensively metabolised by CYP3A4. Concomitant administration with clarithromycin increases the plasma levels and the risk of myopathy.<ul><li>Simvastatin — do not prescribe clarithromycin to a person taking simvastatin. If treatment with clarithromycin cannot be avoided, stop treatment with simvastatin temporarily.</li><li>Atorvastatin — avoid concurrent use with clarithromycin. If concurrent use cannot be avoided, prescribe the lowest dose of atorvastatin.</li></ul></li><li>Warfarin — clarithromycin increases the anticoagulant effect of warfarin. Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li><li>Drugs that prolong the QT interval (such as amiodarone, or sotalol) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is contraindicated.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">BNF 76, 2018</a>]</p><!-- end field 123aae18-6a32-4a0c-a1c9-a75b0129de34 --><!-- end item 21b50b59-526f-4c2b-9c54-a75b0129dd3e -->","subChapters":[]},{"id":"530e3ccb-4d9f-5f37-bd82-d92c4f8fabb3","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field bd8dda59-14ec-435d-8ee5-a75b0129fe06 --><h3>Can I prescribe clarithromycin to a woman who is pregnant or breastfeeding?</h3><!-- end field bd8dda59-14ec-435d-8ee5-a75b0129fe06 -->","summary":"","htmlStringContent":"<!-- begin item 73777a61-bc92-43d0-ad67-a75b0129fe33 --><!-- begin field 083508af-744d-4112-a9e7-a75b0129fe06 --><h4>Pregnancy</h4><ul><li>Avoid clarithromycin (especially in the first trimester), unless the benefit outweighs the risks.<ul><li>The UK Teratology Information Service (UKTIS) states that there is less available data for use of clarithromycin than erythromycin and although available evidence does not suggest an increased risk of congenital malformation, one cannot be excluded — where a macrolide is clearly indicated, erythromycin is the preferred choice during pregnancy as there is more documented experience of its use than for other macrolides.</li></ul></li></ul><h4>Breastfeeding</h4><ul><li>Clarithromycin is excreted into breastmilk. Avoid use in women who are breastfeeding, unless the benefits outweigh the risks — seek specialist advice.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">Fenner, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">UKTIS, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">BNF 76, 2018</a>]</p><!-- end field 083508af-744d-4112-a9e7-a75b0129fe06 --><!-- end item 73777a61-bc92-43d0-ad67-a75b0129fe33 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}